文献速递食管胃疾病与幽门螺杆菌消化内镜消化道肿瘤与早癌

贲门失弛缓症患者食管癌风险:基于全国退伍军人事务部贲门失弛缓症队列的匹配队列研究

Risk of Esophageal Cancer in Achalasia: A Matched Cohort Study Using the Nationwide Veterans Affairs Achalasia Cohort.
PubMed 文献 · Am J Gastroenterol · 2023-11-17

在美国退伍军人中开展的匹配队列研究(1999–2019年),将1,863例贲门失弛缓症患者与7,452例无贲门失弛缓症者按年龄和性别1:4匹配。中位随访5.5年,贲门失弛缓症组食管癌风险显著升高(HR 4.6,95%CI 2.3–9.2),作者认为对该人群可保持高度怀疑并考虑内镜监测。

要点

  • 贲门失弛缓症患者食管癌风险约为无该病者的4.6倍(HR 4.6,95%CI 2.3–9.2)。
  • 贲门失弛缓症组食管癌发病率为1.4/1000人年,诊断至癌变中位时间3.0年。
  • 作者认为贲门失弛缓症患者可受益于高度怀疑和内镜监测食管癌。

核心结论

  • 基于较高的食管癌风险,贲门失弛缓症患者可能受益于高度怀疑和内镜监测食管癌。

研究设计与样本

  • 研究为匹配队列研究,纳入1999年至2019年美国18岁及以上退伍军人。
  • 贲门失弛缓症患者按年龄和性别1:4匹配无贲门失弛缓症者,随访至发生/死于食管癌、非食管癌原因死亡或2019年12月31日研究随访结束。
  • 采用Cox回归模型分析贲门失弛缓症与食管癌风险的关系。

主要发现

  • 分析队列共9,315人(中位年龄55岁;92%男性):1,863例贲门失弛缓症患者匹配7,452例无贲门失弛缓症者。
  • 中位随访5.5年,贲门失弛缓症组发生17例食管癌(3例食管腺癌、12例鳞状细胞癌、2例未知类型),无贲门失弛缓症组发生15例(11例食管腺癌、1例鳞状细胞癌、3例未知类型)。
  • 贲门失弛缓症组食管癌发病率为1.4/1000人年,从诊断贲门失弛缓症至发生食管癌的中位时间为3.0年(Q1-Q3:1.3–9.1)。
  • 贲门失弛缓症患者在随访5年、10年和15年时的食管癌累积发病率高于无贲门失弛缓症者。
  • 贲门失弛缓症患者食管癌风险高5倍(风险比4.6,95%置信区间:2.3–9.2)。

临床怎么用

  • 作者认为,基于较高的食管癌风险,贲门失弛缓症患者可能受益于高度怀疑和内镜监测食管癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Achalasia is a postulated risk factor of esophageal cancer (EC); however, EC-associated risk in achalasia is understudied. We aimed to evaluate EC risk among individuals within the nationwide Veterans Affairs Achalasia Cohort. METHODS: We conducted a matched cohort study among US veterans aged 18 years or older from 1999 to 2019. Individuals with achalasia were age matched and sex matched 1:4 to individuals without achalasia. Follow-up continued from study entry until diagnosis with incident/fatal EC (primary outcome), death from non-EC-related causes, or end of the study follow-up (December 31, 2019). Association between achalasia and EC risk was examined using Cox regression models. RESULTS: We included 9,315 individuals in the analytic cohort (median age 55 years; 92% male): 1,863 with achalasia matched to 7,452 without achalasia. During a median 5.5 years of follow-up, 17 EC occurred (3 esophageal adenocarcinoma, 12 squamous cell carcinoma, and 2 unknown type) among individuals with achalasia, compared with 15 EC (11 esophageal adenocarcinoma, 1 squamous cell carcinoma, and 3 unknown type) among those without achalasia. EC incidence for those with achalasia was 1.4 per 1,000 person-years, and the median time from achalasia diagnosis to EC development was 3.0 years (Q1-Q3: 1.3-9.1). Individuals with achalasia had higher cumulative EC incidence at 5, 10, and 15 years of follow-up compared with individuals without achalasia, and EC risk was 5-fold higher (hazard ratio 4.6, 95% confidence interval: 2.3-9.2). DISCUSSION: Based on substantial EC risk, individuals with achalasia may benefit from a high index of suspicion and endoscopic surveillance for EC.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Low EE, Demb J, Shah SC, et al. Risk of Esophageal Cancer in Achalasia: A Matched Cohort Study Using the Nationwide Veterans Affairs Achalasia Cohort. Am J Gastroenterol. 2023. PMID: 37975607. doi:10.14309/ajg.0000000000002591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。